SomaLogic swaps CEOs amid mounting losses
BOULDER — SomaLogic Inc. (Nasdaq: SLGC) this week elevated a new CEO at the same time the Boulder-based biotechnology company posted lower sales and higher losses for the fourth quarter of the 2022 fiscal year.
Adam Taich, the firm’s former chief business officer and executive vice president of life sciences, is SomaLogic’s interim CEO, taking over from Roy Smythe, who is no longer employed at the company.
SomaLogic has also recently added four new members to its board of directors.
“We are moving into a new and important chapter at SomaLogic, and I am squarely focused on bringing improved operational discipline while managing…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Mosaic Biosciences Inc., a Boulder drug-discovery company that provides protein and antibody therapeutics research to…
-
Medical-device firm Boulder iQ has nearly doubled its Boulder footprint with the purchase of a…
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
-
OnKure Inc., a Boulder precision oncology company, and California-based Reneo Pharmaceuticals Inc. have completed a…
